56. ベーチェット病 Behcet disease Clinical trials / Disease details


臨床試験数 : 76 薬物数 : 110 - (DrugBank : 32) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02648581
(ClinicalTrials.gov)
June 14, 201721/12/2015Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseA Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseBehçet DiseaseDrug: Subcutaneous UstekinumabAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/AAll16Phase 2France
2EUCTR2015-002190-37-FR
(EUCTR)
30/10/201512/01/2016A Study to Evaluate the Efficacy and Safety of Ustekinumab in patients with Behçet diseaseA Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in patients with Behçet disease : STELABEC - STELABEC Behçet diseaseSTELABEC-1: patients with oral ulcersSTELABEC-2 : patients with active posterior uveitis or panuveitis
MedDRA version: 18.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: STELARA
Product Name: STELARA
INN or Proposed INN: Ustekinumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France